NewsSep 10, 2026
Your Apple Watch can tell you something real about aging-related health, just not as a single age. The measures Apple feeds into its new Health Age score are among the better-studied things you can track on your own: fitness, resting heart rate, sleep, HRV, and optional labs. Several are tied to future health outcomes, and several can be improved. The score built on top of them is another matter. As of September 10, 2026, no peer-reviewed study was found showing Apple's Health Age predicts disease or death, so watch the ingredients, not the verdict.
NewsSep 1, 2026
A cloth tape around your middle tells you something a scale can't: whether you're carrying the deep belly fat that drives heart disease and diabetes risk. For most adults, the target is a waist under half your height. That rule is now backed by a 2026 JAMA Network Open analysis and the UK's 2025 NICE guideline, and the tape is the cheapest useful home health number after a blood pressure cuff.
Heart HealthAug 31, 2026
If your systolic runs 140 or higher, getting it under 130 now has randomized evidence for your brain, not only your heart. Intensive blood pressure control lowered new dementia cases by about 15% over seven years, and did it with fewer serious adverse events in the treated group than in usual care. That closes a gap the field has been carrying since SPRINT MIND.
MedicationAug 30, 2026
Yes. On August 28, 2026, the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It joins semaglutide, liraglutide, and dulaglutide as a heart-protection option in this group. What tipped the approval wasn't a lower heart-attack rate. It was fewer deaths.
Heart HealthAug 30, 2026
If you're 70 or older, a statin is worth considering when your chance of a first major cardiovascular event is high enough to make daily medication worth it. The new STAREE atorvastatin trial strengthens that case, but it doesn't turn age itself into a reason to start. It found fewer events in a broad endpoint that included cardiovascular death, nonfatal heart attack, stroke, and coronary revascularization. The reduction was driven mainly by fewer heart attacks and coronary procedures. It did not extend disability-free survival. So the useful question is personal: how much event risk are you trying to prevent?
CholesterolAug 22, 2026
Lipfendra (enlicitide) is the first once-daily oral PCSK9 inhibitor, a pill that lowered LDL cholesterol by about 56 percent beyond a placebo pill in a roughly 2,900-person trial. Its reported list price is about $315 a month, but it has not yet been shown to prevent heart attacks or strokes.
Heart HealthAug 9, 2026
Four changes lower blood pressure with the clearest evidence, no new device or supplement required: a DASH-style eating pattern, cutting sodium, regular exercise, and losing weight if you carry extra. Most start working within weeks. Across trials and meta-analyses they tend to drop the top number by about 3 to 12 points, more if you start higher. What lifestyle can't do is replace urgent care or medication when your risk or your reading demands it.
Heart HealthAug 2, 2026
ApoB is a single blood test that counts artery-clogging particles a normal LDL cholesterol result can miss. For most people, the two numbers rise and fall together, so LDL-C still works reasonably well. But in some people, especially those with high triglycerides, diabetes, extra weight, metabolic syndrome, or very low LDL-C on treatment, ApoB can run high while LDL-C looks reassuring. In those discordant cases, heart attack and atherosclerosis-related risk often follows ApoB more closely. That makes ApoB worth checking if your LDL-C looks fine but your risk picture does not.
Heart HealthAug 2, 2026
A high HDL on your lipid panel is most reassuring when it's modestly high and the rest of your numbers are favorable: low LDL, low non-HDL cholesterol or apoB, low triglycerides, normal blood pressure and glucose. The label "good cholesterol" stops holding at the top of the range. Across large cohorts, risk is often lowest in a middle zone, roughly the 50s through 70s, while very high numbers, around 80 to 90 and above, are linked in several studies to more cardiovascular events or mortality, not less. The useful question isn't how to push HDL higher, but whether the rest of your lipid and metabolic picture is actually favorable.
Heart HealthAug 1, 2026
A coronary calcium score of zero is one of the most reassuring results in cardiovascular prevention. It means no detectable calcified plaque in your heart's arteries right now, and it reliably marks low risk over the next several years. But if you're in your 40s or 50s and your LDL has run high for years, that zero is a snapshot, not a reset. Calcium is a late feature of plaque that starts forming years before it hardens, so a clean scan can miss disease that hasn't calcified yet. The question worth answering is when the zero should settle your prevention plan and when it shouldn't.
Cardiovascular HealthJun 4, 2026
Only about 16% of cardiologists correctly identify where the V1 electrode should go on your chest. Among paramedics, just 5 to 6% place all six chest leads in the right spots. That is not a typo. The people reading your heart tracings are frequently working with tracings recorded from the wrong locations on your body.
This matters because even a two-centimeter shift in electrode position can alter the squiggly lines on an ECG enough to mimic a heart attack, hide one, or trigger a cascade of unnecessary tests and treatments. Research consistently finds that roughly half or more of ECG recordings in clinical settings have at least one significant lead out of place.
Heart HealthJun 4, 2026
Standard cholesterol panels measure how much cholesterol sits inside your LDL particles. But cardiovascular risk depends on the number of atherogenic particles circulating in your blood, not the cholesterol mass they carry. The ApoB test measures that particle count directly. Over the past decade, evidence from genetic studies, prospective cohorts, and clinical trials has shown that ApoB predicts cardiovascular events more accurately than LDL cholesterol (LDL-C) alone, particularly in people with metabolic syndrome, insulin resistance, or elevated triglycerides.
Cardiovascular HealthJun 4, 2026
Mobitz type 2 second-degree AV block is one of those diagnoses that sounds technical but carries a very direct, practical message: your heart's electrical wiring has a problem that tends to get worse, and it usually means you need a pacemaker. Even if you feel fine. What makes it especially tricky is that it is often misidentified on ECG, confused with more benign rhythm patterns that don't require the same level of intervention.
The distinction matters because true Mobitz type 2 is strongly associated with progression to complete heart block, fainting episodes known as Stokes-Adams syncope, and death. Getting the diagnosis right is the difference between watchful waiting and permanent pacemaker implantation.
Cardiovascular HealthJun 4, 2026
Grade 1 diastolic dysfunction shows up on echocardiograms all the time, and it's routinely brushed off. Your heart's relaxation phase is slightly stiff, but your filling pressures look fine, and you probably feel nothing. The problem: community data link this silent finding to higher all-cause and cardiovascular mortality over 15 to 20 years, even when it appears completely isolated with no other echo abnormalities. It also predicts future heart failure, stroke, and end-stage renal disease, particularly when it shows up between ages 40 and 55.
So if someone tells you this is just what happens with aging and not worth worrying about, that's incomplete at best. Grade 1 diastolic dysfunction is the earliest detectable stage of abnormal left-ventricular filling, a point where the trajectory can still be changed.
MedicationsJun 4, 2026
Leqvio (inclisiran) is a twice-yearly injection that lowers LDL cholesterol by silencing PCSK9 production in the liver. Across multiple phase 3 trials enrolling over 3,600 patients, its overall safety profile was comparable to placebo, with injection-site reactions as the main differentiator. Here is what the clinical trial data actually shows about side effects, long-term tolerability, and safety in specific patient groups.
MedicationsJun 4, 2026
Praluent (alirocumab) and Repatha (evolocumab) are injectable PCSK9 inhibitors prescribed when statins alone can't bring LDL cholesterol low enough. Both cut LDL by 50-65% and reduce heart attacks and strokes. The real differences are subtle but worth understanding.
MedicationsJun 4, 2026
Rosuvastatin is the most potent statin per milligram, lowering LDL cholesterol by 43% to 55% across its dose range. Your starting dose depends on cardiovascular risk, how far LDL needs to drop, and whether you have existing heart disease.
MedicationsJun 4, 2026
Repatha (evolocumab) is a PCSK9 inhibitor that lowers LDL cholesterol by about 55-60% on top of statins. It is prescribed when statins alone are not enough or when patients cannot tolerate them. Repatha works differently from statins, targeting a specific protein in the liver rather than blocking cholesterol production. Its side effect profile reflects that difference. Here is what clinical trial data and post-marketing surveillance actually show.
MedicationsJun 4, 2026
Rosuvastatin 5 mg is one of the most studied low-dose statins available. Clinical trial data from over 16,000 patients shows it is well tolerated, with serious side effects occurring at rates similar to placebo.
MedicationsJun 4, 2026
Ezetimibe is an FDA-approved cholesterol absorption inhibitor that lowers LDL-C by 15-20% when used alone and by an additional 25% when added to a statin. It works differently from statins, blocking cholesterol uptake in the small intestine rather than suppressing production in the liver. If you are considering Ezetimibe as part of your cholesterol management, this article covers what the published research says about its side effects, with specific numbers from large trials.
